> ## Content Index
> Fetch the complete content index at: https://www.coios.me/llms.txt
> Use this file to discover other available public pages before exploring further.

# Oncological liquid biopsy is cost-effective in most modelled scenarios across thresholds
- URL: https://www.coios.me/oncological-liquid-biopsy-is-cost-effective-in-most/
- Published: 2026-11-18T13:05:56.000Z
- Updated: 2026-11-18T13:59:01.000Z
- Description: Median incremental net monetary benefit of liquid biopsy in cancer was positive at all eight willingness-to-pay thresholds tested, across 43 modelled scenarios from 21 economic evaluations.
- Author: Daniel Ryan
- Tags: Data, models and systems, Value in health, World, #peer-reviewed, #refines, #item, #source-2026-11, #score-65

This systematic review re-analysed 43 modelled scenarios from 21 economic evaluations of liquid biopsy in cancer. Costs were harmonised to 2024 euros, and net monetary benefit was recalculated under eight willingness-to-pay thresholds. Median net benefit was positive under all eight, ranging from €79.52 to €5,091.21 per patient. Under a common threshold of twice Italian GDP per capita, the median was €1,560.07 per patient. Eight scenarios were dominant, while 17 (39.5%) changed classification across thresholds. Scenarios differed in pathways, assumptions and local costs, were not independent, and lacked patient-level data.

*Why it is interesting: The same modelled costs and QALYs can look cost-effective or not, depending only on the threshold chosen. Two cost-saving scenarios lowered health, which a positive net benefit alone does not reveal.*

Source

[The Journal of Liquid Biopsy, 16 November 2026](https://doi.org/10.1016/j.jlb.2026.100690?ref=coios.me)

Paper

Is liquid biopsy in oncology cost-effective? A comparative analysis and systematic review

Authors

Gottardo A, Galvano A, Bazan Russo TD, Busuito G, Di Marco E, Zanatta P et al.

DOI

10.1016/j.jlb.2026.100690

Full text

[Open copy](https://pmc.ncbi.nlm.nih.gov/articles/PMC13770644/?ref=coios.me) (open-access copy, PubMed Central)

Type

Peer-reviewed article

Design

Systematic review and harmonised comparative re-analysis of economic evaluations; 21 studies, 43 modelled scenarios, costs standardised to EUR 2024, INMB recalculated under eight WTP criteria

Verdict

Refines prior evidence

Driver

[Value in health](https://www.coios.me/d-health-economics/)